Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engert

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study GroupM Sieber, H Bredenfeld, A Josting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Leukemia|August 6, 2011
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphomaM Deckert, A Engert, W Brück, et al.
Blood|December 9, 1998
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study GroupH Tesch, V Diehl, B Lathan, et al.
Leukemia|May 1, 1996
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study GroupM Unterhalt, R Herrmann, M Tiemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2012
Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trialK Behringer, I Thielen, H Mueller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trialsP J Bröckelmann, H Müller, M Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2013
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphomaA E Hay, B Klimm, B E Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study GroupM Sieber, H Bredenfeld, A Josting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's LymphomaJ Lundin, A Osterborg, G Brittinger, et al.
Leukemia|August 6, 2011
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphomaM Deckert, A Engert, W Brück, et al.
Blood|December 9, 1998
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study GroupH Tesch, V Diehl, B Lathan, et al.
Leukemia|May 1, 1996
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study GroupM Unterhalt, R Herrmann, M Tiemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2012
Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trialK Behringer, I Thielen, H Mueller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trialsP J Bröckelmann, H Müller, M Fuchs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2013
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphomaA E Hay, B Klimm, B E Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study GroupV Diehl, J Franklin, D Hasenclever, et al.
Pageof 18